These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16388406)

  • 1. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
    Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
    Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
    Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
    Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
    Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acid and lactone forms of statins on S-warfarin 7-hydroxylation catalyzed by human liver microsomes and recombinant CYP2C9 variants (CYP2C9.1 and CYP2C9.3).
    Shiozawa A; Yamaori S; Kamijo S; Ohmori S
    Drug Metab Pharmacokinet; 2021 Feb; 36():100364. PubMed ID: 33341662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fibrates on metabolism of statins in human hepatocytes.
    Prueksaritanont T; Tang C; Qiu Y; Mu L; Subramanian R; Lin JH
    Drug Metab Dispos; 2002 Nov; 30(11):1280-7. PubMed ID: 12386136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.
    Ishigami M; Honda T; Takasaki W; Ikeda T; Komai T; Ito K; Sugiyama Y
    Drug Metab Dispos; 2001 Mar; 29(3):282-8. PubMed ID: 11181496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
    Transon C; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
    Sakaeda T; Takara K; Kakumoto M; Ohmoto N; Nakamura T; Iwaki K; Tanigawara Y; Okumura K
    J Pharm Pharmacol; 2002 Mar; 54(3):419-23. PubMed ID: 11902809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
    Monostory K; Pascussi JM; Szabó P; Temesvári M; Köhalmy K; Acimovic J; Kocjan D; Kuzman D; Wilzewski B; Bernhardt R; Kóbori L; Rozman D
    Drug Metab Dispos; 2009 Feb; 37(2):375-85. PubMed ID: 18971317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
    Chen C; Mireles RJ; Campbell SD; Lin J; Mills JB; Xu JJ; Smolarek TA
    Drug Metab Dispos; 2005 Apr; 33(4):537-46. PubMed ID: 15616150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors.
    Fujino H; Saito T; Tsunenari Y; Kojima J; Sakaeda T
    Xenobiotica; 2004; 34(11-12):961-71. PubMed ID: 15801541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.
    Sakaeda T; Iwaki K; Kakumoto M; Nishikawa M; Niwa T; Jin JS; Nakamura T; Nishiguchi K; Okamura N; Okumura K
    J Pharm Pharmacol; 2005 Jun; 57(6):759-64. PubMed ID: 15969931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
    Lee CK; Choi JS; Choi DH
    Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Pharm Res; 2001 Jun; 18(6):800-6. PubMed ID: 11474784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
    Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U
    Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.